Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sepsis 1Infections 1Hematologic Neoplasms 1

Interventions

Trimethoprim, Sulfamethoxazole Drug Combination 9Ciprofloxacin 8Voriconazole 5Vancomycin 4Caspofungin 4Amoxicillin-Potassium Clavulanate Combination 4gamma-Globulins 3Fluconazole 3Filgrastim 3Daptomycin 3Antibiotic Prophylaxis 3plerixafor 2liposomal amphotericin B 2Whole-Body Irradiation 2Trimethoprim 2Therapeutics 2Sulfamethoxazole 2Saline Solution 2Rituximab 2Ribavirin 2Polymerase Chain Reaction 2Piperacillin, Tazobactam Drug Combination 2Peripheral Blood Stem Cell Transplantation 2Pentetic Acid 2Moxifloxacin 2Melphalan 2Levofloxacin 2Lenalidomide 2Itraconazole 2Immunoglobulins, Intravenous 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infections × drotrecogin alfa activated × Clear all
NCT00067730 2007-12-07

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Eli Lilly and Company

Phase 4 Completed
7 enrolled
Other hematologic neoplasm

Infections, Sepsis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡